- Home
- KRSA
as of 11-05-2026 3:52pm EST
Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.
| Founded: | 2024 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.5B | IPO Year: | 2019 |
| Target Price: | $44.00 | AVG Volume (30 days): | 144.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.42 | EPS Growth: | 8.26 |
| 52 Week Low/High: | $29.03 - $37.27 | Next Earning Date: | 11-16-2026 |
| Revenue: | $2,074,000 | Revenue Growth: | 3.70% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -26.12 | Index: | N/A |
| Free Cash Flow: | -3314000.0 | FCF Growth: | N/A |
Compare KRSA vs Leading Stocks
See how KRSA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KRSA Korsana Biosciences Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.